SMMT Summit Therapeutics Inc

$SMMT Hey dudes! Whether you’re riding the bull wave or hanging with the bears, get ready to catch some serious waves over the next three weeks! ESMO brings 10 ivonescimab presentations, including major Akeso Phase III data. We’ve got Q3 earnings (date pending), the Nov. 4 shareholder meeting, the Nov. 14 FDA decision target, and possibly a HARMONi-3 readout! Add AstraZeneca’s $2B investment to the mix, and we’ve got one heck of a swell building! Bulls or bears, grab your boards. These next few weeks could be a wild ride!

$SMMT if you’re selling into this news, you’re picking up a penny in front of a steamroller. This is a Very Friendly $SMMT deal. If you think the company should be worth less today than it was a couple of days ago, I can’t help you….

$SMMT If HARMONi-3 shows an overall survival win head-to-head against Keytruda in first-line lung — not just PFS, but people living longer — plus the FDA approval next month, plus China already approved, plus the ADC combos with AZ/Daiichi/Pfizer... you're holding the most valuable oncology asset of the decade.

$SMMT NGL my dream home is riding on this. It’s a humble one in the woods if anyone asks.

$SMMT AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment PUBLISHED MON, OCT 5 20263:44 PM EDT https://www.cnbc.com/2026/10/05/astrazeneca-ceo-says-summit-drug-could-drive-future-cancer-combos.html

$SMMT — Another major ivonescimab collaboration just dropped. Summit is working with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab alongside the TROP2 ADC Datroway across multiple tumor types. That’s on top of AstraZeneca’s recent $2B investment in Summit and the Nov. 14 FDA decision approaching. Ivonescimab is quickly becoming one of the more interesting oncology assets to follow.

$SMMT Assuming SMMT closes today above yesterday’s closing price of $17.31, that will makes 6 of 7 days since the $2B AZ equity investment and trial collaboration was announced, that the day’s closing price has been above the prior day’s closing price. Since that announcement, the first 4 days closed in the $16’s and the following 2 days closed in the $17’s. Today has 30 minutes to go and the stock is currently trading at currently at $17.94 (above yesterday’s closing price). The Q2 earning call occurs in 8 trading days, and the FDA BLA decision is just 27 trading days away; and HARMONi-3, assuming results are presented before the end of the year (two firms wrote in July that they thought timelines could slip into early 2027), is just 59 trading days from today. Will institutions continue to scale into a new or higher positions prior to the earnings call and/or the BLA decision, setting higher lows every few days. Let’s hope so, because that’s the right direction. Long.

$SMMT COOKIN 🔥 - The pieces increasingly suggest Summit is positioning for something much larger than a single-drug approval. AstraZeneca’s $2B strategic investment, today’s proposal to increase authorized common shares to 2 billion, expanding oncology collaborations, and a broadening Phase III pipeline all point toward management building the capital structure and foundation necessary to potentially become a major global oncology company.

$SMMT CNBC segment on treatments being developed in China and translating into western patients, says SMMT will be the 1st true test of this with data later this year. They are bullish on Summit results.

$SMMT Robert Duggan is a biotech legend with the vision, conviction, and patience to swing for something enormous. I’m betting he’s building his next blockbuster and I’m riding with him. Hopefully my next yacht needs a crew instead of a cupholder. 🚀🛥️

$SMMT headline here Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

$SMMT Hey dudes! The closing bell has rung, and we’re officially in after-hours trading! The next three weeks could be one wild ride, with some monster waves headed our way. Bulls and bears, better buckle up! And if you mothers can’t stand the heat, you better get out of the kitchen! This ride ain’t for the faint of heart!

$SMMT As a reminder: Bob Duggan (SMMT Co-CEO) led Pharmacyclics from 2008–2015. In those ~7 years he turned the company around with ibrutinib (Imbruvica), which got FDA approval in 2013, and sold it to AbbVie for ~$21B for $216 a share. When he took over the stock was at $2. He’s said his son’s death from brain cancer is part of why he got into oncology. SMMT’s HARMONi results showed very strong brain mets response; which hopefully will be one of several factors why FDA approves on/before Nov 14. Long.

$SMMT Prior to Nov 14th FDA BLA decision, there are two other key dates: 1) Earnings call (Oct 19, tentative) Investors may hear updates on new trial initiations, partnerships, financial runway, enrollment progress, and critically whether HARMONi‑3 final PFS / interim OS will be presented in Q4 2026 or early 2027. Summit could also potentially signal interest in a Phase III BTC program, given emerging data (see below). 2) ESMO Presidential Symposium (Oct 25) Akeso will present overall survival (OS) results from its Phase III biliary tract cancer (BTC) trial. BTC is a high‑mortality cancer, and a very difficult one to treat, so a statistically significant, clinically meaningful OS win is a major achievement. Regulators will view this favorably when Summit submits future BLA/sBLA filings, because FDA evaluates the totality of evidence across all ivonescimab trials, regardless of indication. Long.

$SMMT Wild to think a little nobody can buy shares of this company on the open market right now for a lower price than a sophisticated big pharmaceutical company just agreed to pay. For all the breathless talk of the market being rigged against the little guy, it’s somewhat surprising to me that opportunities like this are allowed to exist longer than a minute.

$SMMT 83% insider ownership and 4.6 institutions...🤔 if this is approved on Nov. 14 this short squeeze will make Gamestop look like an ant hill!!! Count me in 😝 (and upcoming conference 😍😍😍buy now and you will greatful😉)

$SMMT Citi raised its Summit Therapeutics (SMMT) price target from $40 to $43 on September 29, 2026, following the announcement of AstraZeneca's $2 billion strategic investment.

$SMMT what a jewel. Nothing but good news, hard work and strategic thinking from this biotech company. So happy to have found this.

$SMMT Latest company news, Oct 21, 2026: Summit and the ECOG-ACRIN Cancer Research Group will run EA2251, a registration-enabling Phase II/III study of ivonescimab in first-line advanced biliary tract cancer; site activation is expected to begin in Q4 2026. HARMONi-GI1 data are set for the ESMO Presidential Symposium on October 25. More news in our $SMMT stock hub on Merlintrader. Not investment advice.

$SMMT got almost 3m in this and still loading if this is bobs biggest bet it’s mines too yolo ✨ here for the journey . Cheers longs 🥂